Cisatracurium vs Rocuronium for Chronic Kidney Disease
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 490 (estimated)
- Sponsor
- The University of Texas Medical Branch, Galveston · Other
This trial is looking for patients with chronic kidney disease who need surgery with general anesthesia. Participants will help researchers find out which medication combination is safer during and after surgery.
You may be able to join if
- I am between 18 and 80 years old.
- I have chronic kidney disease as defined by my doctor.
- I am able and willing to provide signed consent.
- I need surgery that requires general anesthesia and neuromuscular blockade.
You may not be able to join if
- I am under the age of 18.
- I am over the age of 80.
- I have end stage renal disease.
- I require dialysis.
- I am pregnant.
- I am in the correctional system.
- I have a documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine.
- My surgery is urgent or requires intubation after the procedure.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Loading trial locations…